AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Zenas BioPharma, Inc.
Video analysis: ZBIO
All videosNo video analysis for this stock yet. Request one from our team.
News: ZBIO
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Analyzing United Therapeutics (NASDAQ:UTHR) and Zenas BioPharma (NASDAQ:ZBIO)
United Therapeutics (NASDAQ: UTHR - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Volatility and Risk United Therapeutics has a beta
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET.
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management's presentations at the following investor conferences: Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m.
Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO
Bank of America Corp DE boosted its position in shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 723.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 388,347 shares of the company's stock after buying an additional 341,187 shares during the period.
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on August 17, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted an aggregate of 11,000 restricted stock units of the Company's common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared to prefilled syringes - - Obexelimab global Phase 2 SunStone SLE trial topline results expected in Q4 2026 - - ZB021 (oral IL-17AA/AF inhibitor) dosing ongoing in Phase 1 trial; initial clinical data expected by year-end - - Four Orelabrutinib abstracts accepted for poster presentation at MSToronto 2026 - - Expanded Board of Directors with the appointment of Christy Oliger, who brings more than 30 years of global biopharmaceutical commercial and operating experience - - CFO to transition to Strategic Advisor to the Board Chair at the end of September - - Cash, cash equivalents and investments of $673.9 million as of June 30, 2026 - WALTHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2026, and provided recent corporate updates.
